A research group from China carried out a single-center, open-label, randomized controlled trial to evaluate the efficacy and safety of Hua Shi Bai Du Granule (Q-14) (or Huashi Baidu 化湿败毒颗粒) ((厚朴,黄芪,苍术,藿香,草果,甘草,半夏,葶苈子,赤芍,茯苓,麻黄,杏仁,大黄,生石膏 Hou Po, Huang Qi, Cang Zhu, Huo Xiang, Cao Guo, Gan Cao, Ban Xia, Ting Li Zi, Chi Shao, Fu Ling, Ma Huang, Xin Ren, Da Huang, Sheng Shi Gao)) plus standard care compared with standard care alone in adults with coronavirus disease (COVID-19). The study recruited 204 patients with laboratory-confirmed COVID-19 who were randomized into the treatment group (n=102) and control group (n=102) from Wuhan Jinyintan Hospital, Wuhan, China, February 27 to March 27, 2020. In the treatment group, Q-14 was administered at 10 g (granules) twice daily for 14 days, plus standard care. In the control group, patients were provided standard care alone for 14 days. They concluded that the combination of Q-14 and standard care for COVID-19 was useful for the improvement of symptoms (such as fever, cough, fatigue, and chest discomfort), but did not result in a significantly higher probability of negative conversion in the SARS-CoV-2 viral assay.
Liu J, et al. Combination of Hua Shi Bai Du Granule (Q-14) and Standard Care in the Treatment of Patients with Coronavirus Disease 2019 (COVID-19): A Single-center, Open-label, Randomized Controlled Trial. Phytomedicine, 2021 Jul 17: 153671.
Read full-text in Phytomedicine